| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | JQ-1:vorinostat (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |